Clinical trial
Effect of Rosiglitazone and Placebo on Carotid Intima Media Thickness in Patients With Insulin Resistance Syndrome and/or Type 2 Diabetes
NCT00306644 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Rosiglitazone and Placebo on Carotid Intima Media Thickness in Patients With Insulin Resistance Syndrome and/or Type 2 Diabetes
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 31, 2002
- Completion date
- November 30, 2004
- Enrollment
- 556 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.